Travere Therapeutics, Inc. $TVTX Shares Sold by Lisanti Capital Growth LLC

Lisanti Capital Growth LLC reduced its stake in shares of Travere Therapeutics, Inc. (NASDAQ:TVTX – Free Report) by 25.0% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 89,230 shares of the company’s stock after selling 29,775 shares during the quarter. Travere Therapeutics comprises approximately 1.4% of Lisanti Capital Growth LLC’s holdings, making the stock its 21st largest position. Lisanti Capital Growth LLC owned about 0.09% of Travere Therapeutics worth $5,254,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently modified their holdings of the company. GAMMA Investing LLC lifted its holdings in shares of Travere Therapeutics by 53.4% in the second quarter. GAMMA Investing LLC now owns 606 shares of the company’s stock worth $34,000 after buying an additional 211 shares in the last quarter. Allworth Financial LP purchased a new position in Travere Therapeutics during the second quarter valued at $47,000. Fifth Third Bancorp purchased a new position in Travere Therapeutics during the first quarter valued at $35,000. Integrated Wealth Concepts LLC purchased a new position in Travere Therapeutics during the second quarter valued at $70,000. Finally, Sterling Capital Management LLC increased its holdings in Travere Therapeutics by 839.5% in the 3rd quarter. Sterling Capital Management LLC now owns 2,950 shares of the company’s stock valued at $174,000 after acquiring an additional 2,636 shares during the last quarter.

Travere Therapeutics Stock Up 0.1%

Shares of NASDAQ TVTX opened at $52.04 on Thursday. The company has a current ratio of 3.00, a quick ratio of 2.95 and a debt-to-equity ratio of 26.72. Travere Therapeutics, Inc. has a 12-month low of $22.59 and a 12-month high of $68.73. The firm’s 50-day moving average price is $56.56 and its 200-day moving average price is $47.34. The stock has a market capitalization of $5.00 billion, a price-to-earnings ratio of -40.34 and a beta of 1.11.

Travere Therapeutics (NASDAQ:TVTX – Get Free Report) last released its quarterly earnings results on Monday, November 2nd. The company reported ($0.55) EPS for the quarter, missing the consensus estimate of ($0.06) by ($0.49). Travere Therapeutics had a negative return on equity of 185.69% and a negative net margin of 18.66%. The company had revenue of $224.56 million during the quarter, compared to analysts’ expectations of $195.29 million. During the same quarter in the prior year, the business posted $0.28 EPS. The company’s revenue was up 36.2% on a year-over-year basis. On average, equities research analysts anticipate that Travere Therapeutics, Inc. will post -0.90 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, CEO Eric M. Dube sold 243,735 shares of the stock in a transaction on Thursday, October 15th. The stock was sold at an average price of $53.82, for a total transaction of $13,117,817.70. Following the sale, the chief executive officer owned 432,886 shares in the company, valued at approximately $23,297,924.52. This represents a 36.02% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Elizabeth E. Reed sold 37,500 shares of the firm’s stock in a transaction on Tuesday, September 15th. The stock was sold at an average price of $62.34, for a total value of $2,337,750.00. Following the completion of the sale, the insider owned 105,389 shares of the company’s stock, valued at approximately $6,569,950.26. This represents a 26.24% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 1,294,029 shares of company stock worth $79,454,261. 4.44% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

Several analysts have commented on TVTX shares. HC Wainwright reiterated a “buy” rating and issued a $67.00 price target on shares of Travere Therapeutics in a research note on Tuesday, September 22nd. Guggenheim cut their price objective on Travere Therapeutics from $89.00 to $78.00 and set a “buy” rating for the company in a research report on Wednesday, November 4th. Piper Sandler reaffirmed an “overweight” rating on shares of Travere Therapeutics in a report on Monday, August 17th. Citigroup boosted their target price on Travere Therapeutics from $70.00 to $85.00 and gave the stock a “buy” rating in a research report on Wednesday, August 5th. Finally, Canaccord Genuity Group boosted their target price on Travere Therapeutics from $70.00 to $72.00 and gave the stock a “buy” rating in a research report on Wednesday, November 4th. Eleven investment analysts have rated the stock with a Buy rating and two have given a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $72.55.

Read Our Latest Stock Analysis on TVTX

Travere Therapeutics Company Profile

(Free Report)

Travere Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing treatments for rare diseases, with an emphasis on kidney and metabolic disorders. The company was formerly known as Retrophin and adopted the Travere Therapeutics name in 2020. Its commercial products include FILSPARI (sparsentan), an oral treatment approved in the United States for adults with primary IgA nephropathy at risk of disease progression, and THIOLA EC (tiopronin), used to help prevent cystine kidney stones in people with cystinuria.

Recommended Stories

Want to see what other hedge funds are holding TVTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Travere Therapeutics, Inc. (NASDAQ:TVTX – Free Report).

Institutional Ownership by Quarter for Travere Therapeutics (NASDAQ:TVTX)

Receive News & Ratings for Travere Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Travere Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.